|
|
|
New Paradigm for R&D Collaborations |
|
|
|
|
● |
Establish a Phase I Unit in Chang Gung Memorial Hospital, Linkou. |
● |
Co-developing pipeline small molecules, biologics, or device/diagnostics and sharing the IP with international academia or industrial partners. |
● |
Establish Academic-Industrial Collaboration Center under R&D Committee of CGMF to facilitate the process. |
|
|
|
|
|
|
|
● |
Academia should assume a new role to not just for new targets discovery but also repurposing approved or abandoned drugs as PI-initiated trials. |
● |
New indications of approved drugs should be based on preclinical evidences. |
● |
Partnership between industry, government, academia, and non-profit organizations should be encouraged by universities, hospitals, and government (regulatory). |
● |
Intellectual properties (IPs) owned by international collaborative organizations or industrial partners can be developed or have add on value through clinical validation with CGU-CGMH. Likewise, IPs owned by CGU-CGMH can be translated through its collaborative partners. |
● |
Through the joint efforts of the researchers, molecular mechanisms can be discovered and targeted in prevention, diagnosis and therapy of human diseases. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|